At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1 enrolled
Drug / intervention
Nivolumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Ipilimumab, and 2 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 1 participant across 71 sites in 12 countries.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of BMS-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage IV non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesArgentina, Australia, Belgium, Chile, France, Germany, Israel, Italy, Poland, Spain, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartOct 2022
Primary CompletionDec 2022
TodayJul 2026
First PostedAug 13, 2021
Enrollment StartOct 3, 2022
Primary CompletionDec 27, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.9 years ago
Interventions
Nivolumabdrug
Specified dose on specified days
Ipilimumabdrug
Specified dose on specified days
BMS-986207drug
Specified dose on specified days
Placeboother
Specified dose on specified days